Loading...
•
Jun 30, 2023
TransMedics Q2 2023 Earnings Report
Reported financial results with a significant revenue increase driven by the utilization of the National OCS Program.
Key Takeaways
TransMedics reported a strong second quarter with a 156% increase in revenue compared to the previous year. The growth was primarily driven by the increased utilization of the National OCS Program. The company also updated its full-year revenue guidance to $180 million to $190 million.
Net revenue reached $52.5 million, a 156% increase compared to Q2 2022.
The National OCS Program drove approximately 93% of total U.S. OCS cases.
A definitive agreement was signed to acquire Summit Aviation.
Assets and IP related to the Ex-Vivo Organ Support System and LifeCradle Heart Preservation Transport System technologies were acquired from Bridge to Life.
Forward Guidance
TransMedics updated its full year 2023 revenue guidance to be in the range of $180 million to $190 million, which represents 93% to 103% growth compared to the company’s prior year revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...